S-1
Superior Sulcus Tumor
National Cancer Center Hospital EastPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Superior Sulcus Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Center Hospital East | Phase 3 | B |
Durvalumab National Cancer Center Hospital East | Phase 3 | B |
Carboplatin Fundación GECP | Phase 2 | CCC |
Nivolumab Fundación GECP | Phase 2 | CCC |
Same molecule, other indications
S-1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →